← SynDRA
LOMUSTINE
SynDRA canonical compound SYN0000581 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Mechanism of action | DNA synthesis inhibitor |
|---|
| Indication | brain tumors | Hodgkin's lymphoma |
|---|
| Disease area | hematologic malignancy | oncology |
|---|
Mechanisms of action (all sources)
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADRA2A
- ACHE
- LCK
- MMP9
- MMP1
- MC5R
- MC4R
- MC3R
- MAPK3
- MAPK14
- MAPK1
- MAOB
- MAOA
- KCNH2
- NPY2R
- HTR6
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HSPA5
- HRH3
- HRH2
- HRH1
- HMGCR
- NPY1R
- NR3C1
- FYN
- OPRD1
- TDP1
- TBXAS1
- TBXA2R
- TACR2
- TACR1
- SLC6A4
- SLC6A3
- SLC6A2
- SIGMAR1
- PTPRC
- PTGS2
Drug classes
- Alkylating Activity
- Alkylating Drug
- Alkylating Agents
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Noxae
ATC classes
Cross-references
Synonyms
- GLEOSTINE
- Gleostine
- belustine
- chloroethylcyclohexylnitrosourea
- lomustin
- Lomustina
- CCN-U
- Ccnu
- NSC-79037
- Ceenu
- Belustine
- CCNU
- CINU
- Cecenu
- CeeNU
- Chloroethylcyclohexylnitrosourea
- Lomustinum
- Bristol-Myers Squibb Brand of Lomustine
- CCNU [Chloroethyl nitrosoureas]
- Cyclohexyl chloroethyl nitrosourea
- Lomustine medac Brand
- Medac Brand of Lomustine
- Rhone-Poulenc Rorer Brand of Lomustine
- OR5087
- RB 1509
- SRI 2200
- CeeNU (TN)
- Lomustina [INN-Spanish]
- Lomustinum [INN-Latin]
- NPFAPI-06
- CeeNU, CCNU, Lomustine
- Lomustine (USAN/INN)
- Lomustine [USAN:BAN:INN]
- N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea
- 1-(2-Chloroethyl)-3-cyclohexylnitrosourea
- Urea, N-(2-chloroethyl)-N'-cyclohexyl-N-nitroso-
- lomustine (usp-rs)
Reported adverse events
- Myelosuppression
- Thrombocytopenia
- Pulmonary toxicity
- Gastrointestinal disorder
- Hepatotoxicity
Look up LOMUSTINE in the interactive SynDRA portal →